Updated: Clinical characteristics of patients with COVID-19
Dr Siddharth analysed the clinical characteristics of 1,689 #COVID19 patients from 21 publications, and the demographics of 2,198 2019nCoV patients.
COVID-19 in Hong Kong: the end of the beginning?
Watching the daily increase in Covid-19 cases in Hong Kong is scary. However, a more useful analysis is the ‘epidemic curve’, which looks at the date of symptom onset of cases rather than the date of case detection.
How do people get COVID-19 in Hong Kong
Dr Siddharth Sridhar, Specialist in Clinical Microbiology & Infection, looked at the main settings of Covid-19 transmission in Hong Kong (as of 20/2/2020)
2019-nCoV – Summary of the situation in HK as of Feb 6, 2020
Dr Siddharth Sridhar provides a brief overview on the infections with 2019-nCoV in Hong Kong as of Feb 6, 2020. Are they imported cases, local transmissions? And if locally transmitted how closely are the patients related?
How infectious is novel coronavirus (2019-nCoV)
Dr Siddharth Sridhar describes the basic reproduction number – a measure of how ‘infectious’ a pathogen is and how likely it is to spread through a community – for 2019-nCoV, and compares this with the early phases of the SARS and measles outbreaks.
2019-nCoV: how stable are coronaviruses in the environment?
Dr Siddharth Sridhar, looked at how stable coronaviruses are on a variety of environmental surfaces, and provides recommendations to prevent infection with 2019-nCoV.
Who gets severe novel coronavirus (2019-nCoV) infection?
Here, I examined the data of 28 patients from 5 publications who had severe pneumonia due to 2019-nCoV requiring ICU admission and/or resulting in death.
Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?
UPPSALA, Sweden, April 24, 2019 /PRNewswire/ — Researchers of the Erasmus University Medical Center in Rotterdam − the Netherlands, consider that the synthetic and fully resorbable TIGR® Matrix surgical mesh (Novus Scientific AB, Uppsala − Sweden) may reduce frequent risks related to the surgical repair of Sportsman’s hernia.
Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients
On the 31st of July 2018, the FDA approved lusutrombopag (Mulpleta®, Shionogi) for thrombocytopenia in adult chronic liver disease (CLD) patients scheduled for an invasive medical or dental procedure.
